期刊文献+

人乳头状瘤病毒DNA恒温扩增技术在宫颈癌筛查中的应用价值 被引量:10

Application of isothermal HPV DNA amplification test in cervical cancer screening
原文传递
导出
摘要 目的评价人乳头状瘤病毒(HPV)DNA恒温扩增检测技术Isomega应用在高危型别HPVDNA检测及宫颈病变诊断中的可行性及有效性。方法招募2774名30-64岁来自内蒙古自治区健康妇女进行宫颈癌筛查。采用Isomega和cobas4800HPV检测技术进行HPVDNA检测,应用线性探针法(INNO-LiPA)对两种检测方法结果不一致的标本进行分型检测。以病理诊断为金标准,评价Isomega和cobas4800方法检出宫颈上皮内瘤变(CIN)2级及以上病变的有效性和准确性。结果Isomega与cobas4800检出HPVDNA的总一致率为94.84%(Kappa=0.82),检出HPVl6、HPVl8型和其他型别HR-HPV的一致率分别为99.68%(Kappa=0.95)、99.78%(Kappa=0.91)和94.34%(Kappa=0.76)。与INNO-LiPA校正结果比较,Isomega检出HPVl6、HPVl8和其他型别HR-HPV的一致率分别为99.71%(Kappa=0.95)、99.86%(Kappa=0.94)和95.76%(Kappa=0.87);cobas4800的一致率分别为99.82%(Kappa=0.97)、99.86%(Kappa=0.94)和97.51%(Kappa=0.90)。Isomega检出CIN2+(包括CIN2、CIN3和鳞癌)的敏感度和特异度分别为87.76%和82.94%,cobas4800分别为89.80%和85.06%。结论Isomega与cobas4800HPV检测方法的一致性较好,检测HPVl6和18型的准确性高,具有较高的敏感度和特异度.可用于临床检测和大规模人群的宫颈癌筛查。 Objective To evaluate the feasibility and effectiveness of isothermal human papillomavirus (HPV) DNA amplification test as a primary screening test in the early detection of cervical cancer. Methods From June to August 2016, 2,774 women aged 30-64 years old from Inner Mongolia were recruited for cervical cancer screening. HPV DNA was detected by Isomega and cobas4800. INNO-LiPA HPV Genotyping Extra was served as a reference method for the cases whose results were inconsistent by using these two methods. Histological diagnosis was considered as a gold standard to estimate the effectiveness and accuracy of Isomega and cobas4800 for detecting CIN2 or greater. Results The concordance of Isomega and cobas4800 was 94.84% (Kappa = 0.82) for high risk HPV (HR-HPV) , 99.68% (Kappa=0.95) for HPV16, 99.78% (Kappa=0.91) for HPV18 and 94.34% (Kappa=0.76) for other HR-HPV types. The concordances of Isomega and the reference were 99.71% ( Kappa = 0.96) , 99.86% (Kappa = 0.94) and 96.76% ( Kappa = 0.87) for HPV16, 18 and other HR-HPV, respectively, while the concordances of cobas4800 and the reference were 99.82% ( Kappa = 0.97) , 99.86% ( Kappa =0.94) and 97.51% (Kappa= 0.90) , respectively. The sensitivity and specificity of Isomega for detecting CIN2+ (including CIN2, CIN3 and squamous cell carcinoma) were 87.76% and 82.94%, respectively, while those of cobas4800 were 89.80% and 85.06%, respectively. Conclusions The concordances of Isomega and cobas4800 is confident. These two methods can accurately detect the HPV16 and 18 genotyping, and have good sensitivity and specificity for clinical diagnosis and population screening of cervical cancer.
作者 王林 姜明月 秦宇 李莉 吴泽妮 李婷媛 吴婷 陈汶 Wang Lin;Jiang Mingyue;Qin Yu;Li Li;Wu Zeni;Li Tingyuan;Wu Ting;Chen Wen(State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China;Department of Cancer Epidemiology, National Cancer Center~Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;School of Public Health, Xifiang University, Urumqi 830011, China)
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2018年第4期313-318,共6页 Chinese Journal of Oncology
关键词 人乳头状瘤病毒 宫颈肿瘤 筛查 Human papillomavirus Cervical neoplasms Screening
  • 相关文献

参考文献2

二级参考文献18

  • 1陈汶,刘彬,戎寿德,乔友林.人乳头状瘤病毒DNA检测进展[J].中华检验医学杂志,2005,28(5):552-554. 被引量:17
  • 2Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect ot visual screening on cervical cancer incidence and mortality in Tamil Nadu, India : a cluster - randomised trial. Lancet,2007,370:398 - 406.
  • 3Sankaranarayanan R, Nene BM, Shastri SS,et al. HPV screening for cervical cancer in rural India. N Engl J Med,2009,360:1385 -1394.
  • 4Qiao YL, Seltors JW, Eder PS,et al. A new HPV - DNA test for cervical -cancer screening in developing regions: a cross -sectional study of clinical accuracy in rural China. Lancet Oncol,2008,9:929-936.
  • 5Molijn A, Kleter B, Quint W, et al. Molecular diagnosis of human papiUomavirus (HPV) infections. J Clin Virol, 2005, 32 Suppl 1 : S43 -51.
  • 6Wright TC Jr, Massad LS, Dunton C J, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol, 2007, 197 : 346- 355.
  • 7Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology, 2008, 19:342-354.
  • 8ACOG Praciice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol, 2009, 114 : 1409-1420.
  • 9Stoler MH, Wright TC, Jr, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol, 2011, 135: 468-475.
  • 10Arbyn M, Martin-Hirsch P, Buntinx F, et al. Triage of women with equivocal or low-grade cervical cytology results: a meta- analysis of the HPV test positivity rate. J Cell Mol Med, 2009, 13:648-659.

共引文献63

同被引文献124

引证文献10

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部